CD55在胃间质瘤中的表达及其临床意义

Expression and clinical significance of CD55 in patients with gastric stromal tumors

目的探讨胃间质瘤组织中CD55蛋白的表达及其与患者预后的关系。方法收集2010年1月至2012年10月包头市中心医院行手术切除并经病理诊断为原发胃间质瘤60例标本．应用免疫组织化学方法检On,0CD55蛋白表达情况，分析其与胃间质瘤患者的临床病理特征及预后的关系。结果CD55主要表达于细胞质内。CD55的表达与胃间质瘤大小、核分裂象数、2008NIH分级以及初诊时有无肿瘤转移均密切相关（均P〈0．05）。中位随访时间58．5个月，共14例患者出现肿瘤进展。单因素生存分析显示：肿瘤大小、核分裂象数、2008NIH分级、手术根治度、初诊时有无肿瘤转移以及CD55表达均为影响胃间质瘤无进展生存的重要因素（P〈0．001）。多因素生存分析显示：肿瘤大小（HR11．504，95％CI：1．085～122．011，P=0．043）和CD55高表达（HR11．819，95％C1：1．827～76．477，P=0．01）是影响胃间质瘤患者预后的独立危险因素。结论CD55蛋白表达上调可能促进胃间质瘤的发展及转移，并影响患者的预后。

Objective To investigate the expression of CD55 and its implication on prognosis for patients with gastric stromal tumors. Methods Expression of CD55 was detected by immunohistochemistry staining and the correlation between CD55 and clinicopathological features and prognosis were analyzed on 60 cases of primary gastric stromal tumors from January 2010 to October 2012. Results Of the 60 patients with gastric stromal tumors there were 33 males and 27 females. CD55 was mainly located in the cytoplasm of gastric stromal tumors. There was no statistical difference between CD55 expression and patients＇ gender and age （P 〉 0. 05）. Moreover, the expression of CD55 was closely related to tumor size, mitotic counts, 2008 NIH classifications, and distant metastasis at the first visit to the hospital （ P 〈 0. 05 ）. During a median follow-up of 58.5 （range 23 -78） months, 14 patients had tumor progression. Log-rank univariate survival analysis showed tumor size, mitotic counts, 2008 NIH classifications, radical resection, distant metastasis at the first clinical visit and CD55 expression were related to progression-free survival （ P 〈 0. 001 ）. COX multivariate survival analysis showed that tumor size （HR 11. 504, 95% CI： 1. 085 - 122. 011, P = 0. 043 ） and CD55 expression （HR 11. 819, 95% CI： 1. 827 - 76. 477, P = 0.01 ） were independent prognostic factors. Conclusions Up-regulated CD55 might play an important role in the development and metastasis of gastric stromal tumors.